TWI224005B - Pharmaceutical composition for nasal spray in treatment of cold and fever and method for producing the same - Google Patents
Pharmaceutical composition for nasal spray in treatment of cold and fever and method for producing the same Download PDFInfo
- Publication number
- TWI224005B TWI224005B TW87114505A TW87114505A TWI224005B TW I224005 B TWI224005 B TW I224005B TW 87114505 A TW87114505 A TW 87114505A TW 87114505 A TW87114505 A TW 87114505A TW I224005 B TWI224005 B TW I224005B
- Authority
- TW
- Taiwan
- Prior art keywords
- fever
- item
- nasal
- patent application
- scope
- Prior art date
Links
- 206010037660 Pyrexia Diseases 0.000 title claims abstract description 42
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 16
- 239000007922 nasal spray Substances 0.000 title abstract description 32
- 229940097496 nasal spray Drugs 0.000 title abstract description 31
- 238000004519 manufacturing process Methods 0.000 title abstract description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 19
- 239000007921 spray Substances 0.000 claims abstract description 13
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 9
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 9
- 239000011718 vitamin C Substances 0.000 claims abstract description 9
- 238000001914 filtration Methods 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 52
- 229940079593 drug Drugs 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 229940100656 nasal solution Drugs 0.000 claims description 11
- 239000000341 volatile oil Substances 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 8
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 235000000177 Indigofera tinctoria Nutrition 0.000 claims description 5
- 235000001014 amino acid Nutrition 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 229940097275 indigo Drugs 0.000 claims description 5
- 241000510654 Bupleurum chinense Species 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- 241000334160 Isatis Species 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 239000003640 drug residue Substances 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- -1 road Substances 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- 244000180419 Brassica nigra Species 0.000 claims description 2
- 235000011291 Brassica nigra Nutrition 0.000 claims description 2
- CRDNMYFJWFXOCH-BUHFOSPRSA-N Couroupitine B Natural products N\1C2=CC=CC=C2C(=O)C/1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-BUHFOSPRSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- 235000021314 Palmitic acid Nutrition 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 229940124277 aminobutyric acid Drugs 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 230000000762 glandular Effects 0.000 claims description 2
- 235000003642 hunger Nutrition 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- CRDNMYFJWFXOCH-UHFFFAOYSA-N indirubin Chemical compound N1C2=CC=CC=C2C(=O)C1=C1C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-UHFFFAOYSA-N 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052719 titanium Inorganic materials 0.000 claims description 2
- 239000010936 titanium Substances 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 241000202726 Bupleurum Species 0.000 claims 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims 2
- 238000000605 extraction Methods 0.000 claims 2
- 229950005143 sitosterol Drugs 0.000 claims 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 claims 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 claims 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 claims 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 claims 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 claims 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 229940114079 arachidonic acid Drugs 0.000 claims 1
- 235000021342 arachidonic acid Nutrition 0.000 claims 1
- 235000009697 arginine Nutrition 0.000 claims 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 claims 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims 1
- 229910003460 diamond Inorganic materials 0.000 claims 1
- 239000010432 diamond Substances 0.000 claims 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 1
- 239000010977 jade Substances 0.000 claims 1
- 235000014666 liquid concentrate Nutrition 0.000 claims 1
- 229910052759 nickel Inorganic materials 0.000 claims 1
- 235000013930 proline Nutrition 0.000 claims 1
- 229910052711 selenium Inorganic materials 0.000 claims 1
- 239000011669 selenium Substances 0.000 claims 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 claims 1
- 235000015500 sitosterol Nutrition 0.000 claims 1
- 239000004575 stone Substances 0.000 claims 1
- 210000001331 nose Anatomy 0.000 abstract description 10
- 239000010231 banlangen Substances 0.000 abstract description 9
- 210000003928 nasal cavity Anatomy 0.000 abstract description 9
- 206010019233 Headaches Diseases 0.000 abstract description 7
- 231100000869 headache Toxicity 0.000 abstract description 7
- 208000024891 symptom Diseases 0.000 abstract description 7
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 241000213015 Bupleurum scorzonerifolium Species 0.000 abstract description 5
- 206010011224 Cough Diseases 0.000 abstract description 5
- 206010068319 Oropharyngeal pain Diseases 0.000 abstract description 5
- 201000007100 Pharyngitis Diseases 0.000 abstract description 5
- 206010028735 Nasal congestion Diseases 0.000 abstract description 4
- 206010049590 Upper respiratory tract inflammation Diseases 0.000 abstract description 3
- 239000012528 membrane Substances 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 abstract description 2
- 206010041232 sneezing Diseases 0.000 abstract description 2
- 238000004821 distillation Methods 0.000 abstract 1
- 210000003097 mucus Anatomy 0.000 abstract 1
- 239000006196 drop Substances 0.000 description 31
- 230000001754 anti-pyretic effect Effects 0.000 description 22
- 230000000694 effects Effects 0.000 description 22
- 239000002221 antipyretic Substances 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 201000009240 nasopharyngitis Diseases 0.000 description 10
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 239000000344 soap Substances 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 229940072651 tylenol Drugs 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 208000012287 Prolapse Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000007928 intraperitoneal injection Substances 0.000 description 5
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 5
- 229940098462 oral drops Drugs 0.000 description 5
- 210000003800 pharynx Anatomy 0.000 description 5
- 230000036760 body temperature Effects 0.000 description 4
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000007721 medicinal effect Effects 0.000 description 4
- 210000002850 nasal mucosa Anatomy 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010013082 Discomfort Diseases 0.000 description 3
- 201000000297 Erysipelas Diseases 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 241000334154 Isatis tinctoria Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000000954 anitussive effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 230000002110 toxicologic effect Effects 0.000 description 3
- 231100000027 toxicology Toxicity 0.000 description 3
- CRDNMYFJWFXOCH-YPKPFQOOSA-N (3z)-3-(3-oxo-1h-indol-2-ylidene)-1h-indol-2-one Chemical compound N/1C2=CC=CC=C2C(=O)C\1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-YPKPFQOOSA-N 0.000 description 2
- FAMPSKZZVDUYOS-UHFFFAOYSA-N 2,6,6,9-tetramethylcycloundeca-1,4,8-triene Chemical compound CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 235000007575 Calluna vulgaris Nutrition 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- VLXDPFLIRFYIME-GZBLMMOJSA-N Copaene Natural products C1C=C(C)[C@H]2[C@]3(C)CC[C@H](C(C)C)[C@H]2[C@@H]31 VLXDPFLIRFYIME-GZBLMMOJSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010061192 Haemorrhagic fever Diseases 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 2
- 206010027339 Menstruation irregular Diseases 0.000 description 2
- MVZZUMCHPFHUOS-UHFFFAOYSA-N Patchoulane Chemical compound CC1CCC(C2(C)C)CC3C12CCC3C MVZZUMCHPFHUOS-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 206010043521 Throat irritation Diseases 0.000 description 2
- VQQVWGVXDIPORV-UHFFFAOYSA-N Tryptanthrine Chemical compound C1=CC=C2C(=O)N3C4=CC=CC=C4C(=O)C3=NC2=C1 VQQVWGVXDIPORV-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 2
- PFXFABJPDNHACA-UHFFFAOYSA-N alpha-copaene Natural products CC(C)C1C2CC(=CCC2C3(C)CC13)C PFXFABJPDNHACA-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940125716 antipyretic agent Drugs 0.000 description 2
- 235000013405 beer Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052797 bismuth Inorganic materials 0.000 description 2
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 229930006739 camphene Natural products 0.000 description 2
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- VLXDPFLIRFYIME-BTFPBAQTSA-N copaene Chemical compound C1C=C(C)[C@H]2[C@]3(C)CC[C@@H](C(C)C)[C@H]2[C@@H]31 VLXDPFLIRFYIME-BTFPBAQTSA-N 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 208000021760 high fever Diseases 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 229940116411 terpineol Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- ITYNGVSTWVVPIC-DHGKCCLASA-N (-)-allo-Aromadendrene Chemical compound C([C@@H]1[C@H]2C1(C)C)CC(=C)[C@@H]1[C@H]2[C@H](C)CC1 ITYNGVSTWVVPIC-DHGKCCLASA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- CXENHBSYCFFKJS-VDQVFBMKSA-N (E,E)-alpha-farnesene Chemical compound CC(C)=CCC\C(C)=C\C\C=C(/C)C=C CXENHBSYCFFKJS-VDQVFBMKSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- PHZOWSSBXJXFOR-UHFFFAOYSA-N 2-Propenyl glucosinolate Natural products OCC1OC(SC(CC=C)=NOS(O)(=O)=O)C(O)C(O)C1O PHZOWSSBXJXFOR-UHFFFAOYSA-N 0.000 description 1
- OEZJLUBWUDVTSS-UHFFFAOYSA-N 2-chloro-1,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C([N+]([O-])=O)C(Cl)=C1 OEZJLUBWUDVTSS-UHFFFAOYSA-N 0.000 description 1
- WPRSYXIOJJRNKW-UHFFFAOYSA-N 2-hydroxybut-3-enyl thiocyanate Chemical compound C=CC(O)CSC#N WPRSYXIOJJRNKW-UHFFFAOYSA-N 0.000 description 1
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 241000218691 Cupressaceae Species 0.000 description 1
- HMFHBZSHGGEWLO-IOVATXLUSA-N D-xylofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H]1O HMFHBZSHGGEWLO-IOVATXLUSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 229920004142 LEXAN™ Polymers 0.000 description 1
- AYXPYQRXGNDJFU-AOWZIMASSA-N Ledol Chemical compound [C@@H]1([C@](CC[C@@H]2[C@H]3C2(C)C)(C)O)[C@H]3[C@H](C)CC1 AYXPYQRXGNDJFU-AOWZIMASSA-N 0.000 description 1
- CKZXONNJVHXSQM-UHFFFAOYSA-N Ledol Natural products CC(C)C1CCC(C)(O)C2C3CC(C)CC123 CKZXONNJVHXSQM-UHFFFAOYSA-N 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 239000004418 Lexan Substances 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010068956 Respiratory tract inflammation Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- PHZOWSSBXJXFOR-MYMDCHNCSA-N Sinigrin Natural products S(=O)(=O)(O/N=C(\S[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)/CC=C)O PHZOWSSBXJXFOR-MYMDCHNCSA-N 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- KEIZXGINFPDITQ-UHFFFAOYSA-N UNPD138008 Natural products C1=C(O)C(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(COC3C(C(O)C(O)C(C)O3)O)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 KEIZXGINFPDITQ-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 102000011759 adducin Human genes 0.000 description 1
- 108010076723 adducin Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- WUOACPNHFRMFPN-UHFFFAOYSA-N alpha-terpineol Chemical compound CC1=CCC(C(C)(C)O)CC1 WUOACPNHFRMFPN-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000001775 anti-pathogenic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- UIDUJXXQMGYOIN-UHFFFAOYSA-N aromadendrin Natural products CC1(C)C2C1CCC(C)C1C2C(C)CC1 UIDUJXXQMGYOIN-UHFFFAOYSA-N 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000035565 breathing frequency Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 208000020670 canker sore Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- SQIFACVGCPWBQZ-UHFFFAOYSA-N delta-terpineol Natural products CC(C)(O)C1CCC(=C)CC1 SQIFACVGCPWBQZ-UHFFFAOYSA-N 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- BXWQUXUDAGDUOS-UHFFFAOYSA-N gamma-humulene Natural products CC1=CCCC(C)(C)C=CC(=C)CCC1 BXWQUXUDAGDUOS-UHFFFAOYSA-N 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- QBNFBHXQESNSNP-UHFFFAOYSA-N humulene Natural products CC1=CC=CC(C)(C)CC=C(/C)CCC1 QBNFBHXQESNSNP-UHFFFAOYSA-N 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- COHYTHOBJLSHDF-BUHFOSPRSA-N indigo dye Chemical compound N\1C2=CC=CC=C2C(=O)C/1=C1/C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-BUHFOSPRSA-N 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- OVSQVDMCBVZWGM-QCKGUQPXSA-N isoquercetin Natural products OC[C@@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@@H]1O OVSQVDMCBVZWGM-QCKGUQPXSA-N 0.000 description 1
- 235000008800 isorhamnetin Nutrition 0.000 description 1
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 1
- UIDGLYUNOUKLBM-GEBJFKNCSA-N isorhamnetin-3-O-rutinoside Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)O2)O)=C1 UIDGLYUNOUKLBM-GEBJFKNCSA-N 0.000 description 1
- BGLPQQKZNUKSAR-UHFFFAOYSA-N isorhamnetin-3-O-rutinoside Natural products COc1ccc(cc1O)C2=C(OC3OC(COCC4OC(O)C(O)C(O)C4O)C(O)C(O)C3O)C(=O)c5c(O)cc(O)cc5O2 BGLPQQKZNUKSAR-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- IEPKWJCBNGNVDF-UHFFFAOYSA-N narcissin Natural products OC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(O)C(O)C(COC3C(C(O)C(O)C(C)O3)O)O2)O)=C1 IEPKWJCBNGNVDF-UHFFFAOYSA-N 0.000 description 1
- 235000013557 nattō Nutrition 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- QKFAFSGJTMHRRY-OCFLFPRFSA-M potassium;[(e)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanylbut-3-enylideneamino] sulfate Chemical compound [K+].OC[C@H]1O[C@@H](S\C(CC=C)=N\OS([O-])(=O)=O)[C@H](O)[C@@H](O)[C@@H]1O QKFAFSGJTMHRRY-OCFLFPRFSA-M 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000017291 sinigrin Nutrition 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 229930006978 terpinene Natural products 0.000 description 1
- 150000003507 terpinene derivatives Chemical class 0.000 description 1
- PCZXEAAHGUQDNV-XBNKRBCZSA-N tetrahymanol Natural products CC1(C)CC[C@]2(C)CC[C@]3(C)[C@H]4CC[C@H]5[C@@H](CC[C@H](O)C5(C)C)[C@]4(C)CC[C@@]3(C)[C@@H]2C1 PCZXEAAHGUQDNV-XBNKRBCZSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Description
1224005 九、發明說明: 【發明所屬之技術領域】 本發明係有關一種發燒感冒喷(滴)鼻液劑之醫藥組成物及其 ‘法,將该狹葉柴胡(Bupleurum Scorzonerifolium Willd)、板 藍根(Radix Isatidis Indigotica)、大青葉(Folium Isatidis)以 烈煮後並以提取及濾出藥液之方式,將所含之成分提取及濾出 後,再將此藥液與維生素C混合製成藥劑,使製成之藥劑可供患者 直接喷(滴)至鼻腔内部,由鼻腔粘膜吸收後,具有退燒解熱、鎮 痛、緩解感冒症狀’如頭痛、鼻塞、咳漱、咽喉痛、喷嗓、流洋 及全身不適等感冒症狀之功效,也適用於各種感染性疾病引起之 發燒,尤其以上呼吸道炎症更為適宜。 【先前技術】 感冒,一般人多認為是微不足道之病症,其實,感冒是一種 傳染力很強的病毒性傳染病。其特徵為一組可以識別的常見徵狀 一倦怠、發熱、流淚、鼻塞、頭痛、咽喉乾燥或疼痛。許多病毒 都可以引起感冒。感冒病毒十分微小,可以輕易通過鼻道中的過 濾網,溜進人體,這個過濾網通常只能捕捉體積較大細菌。病毒 迅速增殖,侵害鼻和咽喉,引起常見感冒徵狀。有時會引起併發 症如肺炎或支氣管炎。若是處理不當,甚至會致死。事實上,感 冒是一種不可忽視的常見疾病。 治療感冒在西醫治療方面,不外乎服用抗生素退燒、類固醇 緩解鼻基、抗組織胺等緩解感冒症狀,再加上多喝水、多休息。 1224005 -般而言西賴效比較迅速確實,但抗生素所產生的抗藥性,類 固醇對人體傷害的毒性,化學物質對人體臟器的損害都是現代人 們所熟知的不良作用。而且上述化學藥物對於發燒感冒的缓解、 預防也不盡理想。化賴、感胃藥物在劑型方面—般常用的有膠 囊、綻劑、栓劑、口服液、鼻喷(滴)劑。 感冒的防治在巾醫藥方面,—般由解表藥為主組成 ,以發汗 為主’達到疏散外邪。用以解除表證的方劑,統稱為解表劑。解 表方藥的功效主要有三方面,⑴發汗,通過發汗可_表之邪, 發汗還可以防止病邪傳裏;⑵解肌,解肌是指邪已深入一層,汗 雖出而表證未解,須用疏通肌表,解除肌表之邪;⑶透療,解表 方藥中有些㈣導賴向表’促使贿透發,由於外邪有寒熱之 分’人體有虛症和實症之別’故解刻又分為辛溫解表(用於外感 風寒表證)’辛涼解表(用於外感風熱表證)和扶正解表(用於體質 素虛又感外邪而引起的表證)三大類。中草藥製劑方面常用中藥有 私^ /野(液)劑為主。它有使用安全、副作用小的伽;但有藥 效緩慢,使用不便的缺點。 退燒祛熱方面,除了化學藥物和中草_有不同程度的效果 外尚有物理降溫··如冰敷、酒精擦浴、冰水灌腸等等方法。儘 ^上述方法在臨床上也有—定效果,但也有不纽床病例使用上 ^方法後’體溫非但不降,反而有上升的趨勢。其中冰敷與酒精 务理降溫,因病人高熱絲,難以接受,而且使職不方便。 1224005 综觀上述巾、西㈣醫治發燒、感胃、退祕理治療,不論 西藥、帽或物珊溫,每種綠都存在料完善缺點。 【發明内容】 如果有-種能迅速退燒、緩解感胃症狀、無副伽而且又使 用方便、男女老少都可適㈣退燒感胃製劑,聊是-個非常有 意義的伽。本發明主要特色能有效溶合中、西感f藥和物理退 燒的全部優點於-體而去除全部缝,謂人類應是财意義的 發明。 本發明是以純祕藥粒,組織有效成份,將能迅速退燒、 緩解感冒的藥液製成鼻喷劑。再利用人體生理、器官的特點,從 鼻腔粘膜給藥,避開藥物受腸胃P h值或酶的破壞,直接由鼻腔 粘膜吸收,避免藥效經口服時受肝臟首過作用的破壞,可以減少 藥物對肝臟的毒性及副作用。以達到具有迅速退燒、緩解感冒各 種症狀,女全平無副作用、使用方便,男女老幼皆適用,且攜帶 方便的天然植物藥製成退燒、緩解感冒的鼻喷劑。而且在劑型方 面’嘴(滴)劑對於不能或吞服物困難的患者或兒童尤其方便。 本發明之發燒感冒喷鼻液(滴)劑之醫藥組成物包括: 狹葉柴胡(Bupleurum Scorzonerifolium Willd)、板藍根(Radix Isatidis Indigotica)、大青葉(Folium Isatidis)及維生素C, 將前述之醫藥組成物提取製成藥劑後,藉以噴(滴)至鼻腔,由鼻 腔钻膜吸收,以達到退燒解熱、鎮痛、緩解感冒症狀,如頭痛、 鼻塞、咳嗽、咽喉痛、喷嚏、流涕及全身不適等感冒症狀之功效, 7 1224005 也適用於各誠引起之發練,尤其社呼吸道炎症更
月經不調’氣虛下陷之脫肛,子宮脫垂,胃下垂。 本發明之醫藥組成物之板藍根(Radix Isatidis lndig〇tica) 斑,高熱頭痛,大頭 水痘,麻療,肝炎, 具有清熱,解毒,涼血,利咽。主治溫毒發斑, 痕疫,喉丹#,丹毒,痒腿,喉痒,瘡腫,水痛 流行性感冒。 本發明之醫藥、组成物之大青葉⑽iumIsatidis)具有清熱解
本發明之醫藥組成物之維生素C具有預防感冒,增強抵抗 力,減輕感冒症狀。主治濾過性病原體所引起之感冒。 係有關本發明之詳細說明及技術内容,現配合圖表說明如下: 【實施方式】 請參閱「圖1所示」,係本發明之發燒感冒鼻喷(滴)劑之製作 流程示意圖。如圖所示:本發明之發燒感冒喷鼻液(滴)劑之醫藥 組成物及其製法,而該醫藥組成物包括:25〇〜3〇〇§狹葉柴胡 (Bupleurum Scorzonerifolium Willd)、120〜144g板藍根(Radix Isatidis Indigotica)、12G〜144g大青葉(Folium isatidis)& 8 1^24005 10 12g維生素C ’將别述之醫藥組成物提取製成藥劑後,藉以喷 或用滴至鼻L内膜’自鼻脚罐吸收,可達到退燒解熱、鎮痛、 緩解感冒症狀,如·、鼻塞、铺、咽喉痛、対、流洋及全 身不適等感W症狀功效,亦適驗各贼染性疾病狀之發燒, 尤其以上呼吸道炎症效果更佳。 而上述各醫藥組成物所含之化學成份及藥理方面與功能及主 治上,都具有娜醫療效果,本發縣各醫餘成物分別說明如 下: 1、狹葉柴胡(Bupleurum Scorzonerifolium Willd) 【化學成份】 狹葉柴胡之根含揮發油,該揮發油内含有松油烯(冷 -terpinene)、擰檬烯、樟烯(camphene)、卢—小茴香稀(冷 -fenchene)、胡薄荷酮、異龍腦(is〇b〇rne〇i)、沒―松油醇(冷 -terpineol)、芳樟醇、α —珀圯烯(α—copaene)、葎草烯、^ 金合歡烯(a-farnesene)、香燈烯(aromadendrene)、順式的和反 式的丁香烯、yS -欖香烯(点-elemene)、r 一衣藍油烯(7 -muurolene)、廣藿香烷(patchoulane)、努特卡花柏嗣、制叭醇 (ledol)。又含柴胡總式〇·ΐ5%,其中柴胡皂式a〇.05%、柴胡急 式d微量、柴胡皂武c〇·跳。地上部分含黃酮類化合物:山索 式、山柰紛-7-鼠李糖式、槲皮素(quercetirO、異榭皮素 (isoquercetin)、異鼠李素(isorhamnetin)、芸香武(rutin)、 9 !224〇〇5 水仙(narcissin)。 【藥理方面】 有鎮痛作用,以小鼠壓尾法或醋酸扭體法均證明了口服$胡 粗皂式有_的鎮痛侧。用t擊鼠尾法實驗,證實柴胡息式 478mg/kg(l/4LD50)能使痛閾明顯增高。柴胡粗息武元a與糖 殘餘物腹腔注射50mg/kg或l〇Gmg/kg均能抑制小鼠腹腔注射= 引起的減反應,糖餘雜物職迫法所鱗財鶴鎮痛^ 用。有人認為_皂也可通過鬆弛平滑崎張秘揮鎮痛作用。 有鎮咳作用,柴胡總皂式及柴胡粗皂式元轉缝__ 用’機械舰射紐明,豚鼠腹驗射總皂式触的_為 9· ling/kg ’其效果與魏可待因7. 6 mg/kg相近。柴胡粗阜式元a 的鎮咳作用與劑量有關’豚鼠腹腔注射⑽~2()()mg/kg鎮咳作用最 明顯。 、 【功能與主治】 —具有解表退熱’疏肝解郁,升舉陽氣。崎主治外感發熱, 寒熱往來,雜,肝㈣魏脹頭痛職,月經不調,氣虛下陷 之脫肛,子宮脫垂,胃下垂。 2、板藍根(Radix isatidis Indig〇tica) 【化學成份】 板監根根含憾Gnchgotin,indig〇),款玉紅(祕耐小 /5谷田醇(万-讲⑽的丨)、r 谷留醇(卜5丨t〇ster〇丨)以及多種氨基 1224005 酸:精氨酸(arginine)、谷氨酸(glutamic acid)、赂氨酸 (tyrosine)、脯氨酸(proline)、纈氨酸(valine)、τ-氨基丁酸 (r -aminobutyric ack〇、還含黑芥子式(sinigrin)、彀武 (indoxy卜/5-glucoside),色氨銅(tryptanthrine),l-硫氰酸一2— 輕基丁 -3-烯(1-thiocyano-2-hydroxy-3-butene)、表告伊春
CepigoitrirO、腺式Udenosine}、棕櫚酸(palmitic acid}、蔗 , 糖(sucrose)和含有12%氨基酸的蛋白多糖。
【藥理方面】 I 有抗細菌、病毒作用,在體外試驗,1〇〇%板藍根水煎液對金 頁色葡萄球菌,表皮葡萄球菌有抑菌作用。單層乂沈〇—耶的細胞用 50〇/〇組織細胞感染量(TCID5〇)出血熱病毒吸附,板藍根注射液做抗 病毒實驗,結果1:1〇〇板藍根對腎病綜合征出血熱病毒有明 顯的殺滅作用。板藍根抽提物能抑制病毒侵染并有抑制增殖作用。 對免疫凋節作用,板藍根多糖25呢/故、50mg/kg、l〇〇mg/kg 腹腔注射可明顯增強小鼠對二硝基氯苯(1^(:幻的遲發型變態反鲁 應’誘導體内淋巴細胞轉化和增強脾細胞的自然殺傷細胞(Νκ)活 吐。腹腔注射板藍根多^5〇 mg/kg可顯著促進小鼠免疫功能,其 表見為此明顯增加正常小鼠脾重,白細胞總數及淋巴細胞數,對 氫化可的鬆職免疫魏抑制小鼠脾指數,自細胞總數及淋巴細 胞數的降低有明顯對抗作用,顯著增強二石肖基氯苯所致正常及環 鱗胺所致免疫抑制顿崎發魏敏反應;糾,還能增強抗體 11 1224005 形成細胞功能,增加小鼠靜注碳廓清速率。 【功能與主治】 清熱,解毒,涼血,利咽。主治溫毒發斑,高熱顯痛,大頭 瘟疫,喉丹瘀,丹毒,痄腮,喉痒,瘡腫,水痘,麻疼,肝$ 流行性感冒。 3、大青葉(Folium Isatidis) 【化學成份】 葉含靛藍(indigo,indigotin),菘藍式(isat
Ldn β),散玉 紅(indirubin)。還含鐵、鈦、錳、鋅、銅以及鈷、鑪 研、碼、絡, 砷等無機元素。菘藍式水解可變為靛藍和呋喃木糖分 (D-xylo-5-hexulofuranosonic acid) 。 y ,酉夂 【藥理方面】 抗病原微生物作用,大青葉煎劑體外試驗對金黃色葡萄球 菌,甲型鏈球菌、腦膜炎雙球菌、肺炎鏈球菌、卡他球菌、傷寒 杆菌、大腸杆菌、流行杆菌、白喉杆菌以及痢疾杆菌均有一定抑 制作用。大青葉對乙型腦炎病毒、月思腺炎病毒、流感病毒等= 抑制作用。此外,大青葉尚有殺滅鉤端螺旋體作用。 【功能與主治】 清熱解毒,涼A消斑。主治瘟熱病高熱煩渴,神昏,斑疹, 土jk 血’ Θ舄痒】·,丹毒,喉痒,口瘡,疗月思。 4、維生素C(維他命C) ί2 1224005 【化學成份】 由碳、氫及氧所組成,分例約為6 : 6。 ‘ 【藥理方面】 預防感冒,感冒的症狀有,發燒、惡寒、全身無力、激烈咳 漱、瘦、鼻塞、頭痛、關節痛等等。感冒大多是因濾過性病原體 . 引起的,所以,身體會虛弱,如果再次受細菌感染,容易引發肺 · 炎、支氣管炎、扁桃腺炎、髓莫炎等嚴重疾病。 【功能與主治】 預防感冒,增強抵抗力,減輕感冒症狀。主治濾過性病原體 所引起之感冒。 再將上述之醫樂組成物,分別以提取及濾、出之方式,將各醫 藥組成物中所含之成份提取及濾出後,再加以混合合併製成,可 供喷(滴)入患者鼻腔粘膜吸收之發燒感冒鼻喷(滴)劑,而製法過 程如下列之步驟: 第一步驟,提取揮發油,將250〜300g狹葉柴胡先用一倍量之馨 水/又/包2小日寸,再加四倍1之水煎煮,以水蒸汽蒸館法,提取揮發 油2ml〜2· 4 W,再濾出藥液1000ml〜1200ml,再將揮發油、濾出液 和藥殘渣分別用容器暫存; 第二步驟,將120〜144g板藍根、120〜144g大青葉分別加入七 倍量的水煎煮1小時後並過濾,將過濾液用容器暫存; 第三步驟,係將第一步驟及第二步驟提取或過濾後所剩餘之 13 1224005 藥殘渣混合後,再加人_紋錢五倍量之水赫〗小時,職 出液^然後加四倍量之水煎煮40分鐘,再滤出液合併;^ 第四步驟,合併上述三份濾、出液,並濃縮到ω藥液相當於以 生樂。再將前述放冷加入95%乙醇到含醇量7〇% ; 第五步驟,縣上述靜體辦,财,时 藥 lg; f六步驟,再胸〜2.4ml揮發油及1()〜12§維生素C,溶解後 加入藥液中,混合過濾後,分裝即得。 上述之醫藥組成物經提取製成噴(滴)鼻劑,細)鼻劑不受 月腸Ph值或酶的破壞,直接從鼻腔誠吸收。不但避免口服時受 :臟首過作用的破壞’而且又可減少藥劑對肝臟的毒性或副作 。樂劑在鼻職膜吸收比π服的預少,伽的時耻一般口 月艮作用快’對雜或吞服藥物_的患者錢童,_鼻給藥較 且在上述各醫藥組成物製成發燒感冒嘴鼻液㈤劑藥劑後, 在解熱作用、毒理研究的實驗上都具妓好效果及安全性,讓窜 用時’可安心使用。而前述所提之解熱作用、毒理研究= 貝驗結果及方法說明如下: 一、噴鼻液(滴)的解熱作用方面: 【實驗材料】 1、噴鼻(滴)劑每含生藥2g, 臨床用藥4為錢每十公斤體重 14 2滴(即約〇· lml),十分鐘内滴完,連用10次,累計用藥量每公斤 體重相當於生藥約〇.2g,實驗前將喷鼻液(滴劑)稀釋,配成所需 的藥物濃度。 2、 安乃近(Analgin)注射液,武漢製藥廠生產,批號9511〇4, 規格〇· 5g/ml,臨床嬰幼兒用20%溶液滴鼻,每次每侧鼻孔卜2滴, 即每次最大用藥量約4〇mg時,嬰幼兒平均體重按1〇kg計算,每公 斤體重給藥制44mg時,實麟將安乃近注射_釋,配成所需 的藥物濃度。 3、 泰諾退熱π服滴液(mEN〇L children S P.s LIQUID), 由美國強生公司生產,批號SGM199,每瓶Ι5πα,每Q.8ml含80mg對 乙我氨基紛(醋氨紛Acetaminophen),臨床按年齡或體重給藥, 每a斤體重-人給藥里約〇· 12mi,即給予乙統氨基酸約121111。 4生理鹽水,河南省平頂山市製藥廠生產,批號讀。 5 ^ l〇W^>S##t^(Themingling ferment liquid for fresh beer),取新鮮啤酒酵母懸液,抽渡,取遽渣用生理鹽水反 覆祕’離心後,棄去上清液,則· 5驗甲基纖維素配成順的濃 度。 6 Wistar大乳,體重m〜·g,由河南醫科大學實驗動物 中心提供。 【方法與結果】 實驗在室溫20〜25 t:鉻彼卞A〆/ 條件下進行(請參閱「表1」所示),取 1224005 心加大鼠’祕’體錯G〜21Gg,實驗翻肛表稍測量義礎 體溫二次,對體溫波動錢扣的大鼠皮下注射娜的啤酒酵母縣. 液麗/kg,注射4小時後再次量測體溫,選用體溫升高lt以上了 - 且升溫相近的大鼠50隻進行實驗,將大鼠隨機均分5組,即喷富 液⑻高偷,偷低繼,安她,細細^、 劑組和空自對驗(如表〗之噴鼻液(_)料轉母雜 溫的影響α,卿)),綠·,騎驗_岭試物滴鼻給華, 每次〇.14ml/kg,10分鐘内滴完,伽分鐘給藥-次,連續給_參 次總給藥體積均机4ml/kg,兩個嘴鼻液(_)組分別給稀釋後 兩組濃度的喷鼻液(滴劑),總給藥量,高劑量組相當於生藥 Ug/kg ’低劑量相當於生藥12 _,安乃近組給予稀釋後的 安乃近注射液’安乃近累計用量為〇. 〇8 g/kg,泰諾退熱口服滴劑 組給泰諾退熱口服滴劑’總給藥量飢14_對乙我氨美紛,* 白對照組給予等體積的生理鹽水,分別於末次的q 5、 時再次測量體溫’實驗結果見表。(注:喷鼻液的劑量按給予的生φ 藥劑量’泰諾退熱口服滴劑_量按所含對乙統 與空白對照組比較*Ρ<〇.()5 **—p<G(n。 . 實驗結果表明:喷鼻液(滴劑),泰諾退熱口服滴劑,安乃近. 注射液滴鼻給_有不囉度的解熱個,與空白對照組比較, 具有顯著性和非f顯著性差異,在三種受試_巾,安乃近的解 熱效果較弱’只在給藥後兩小時才錢著的解熱翻⑽〇5), 16 1224005 噴鼻液高㈣組和與其臨床㈣倍數铜的錢 與空白對照組比較,給藥0.5小2、4 ;:乍用較強 . ^ T勺有非书顯著的解熱 乍用U解熱過程上看泰諾賴後近期效果較好, (滴)作用持續時間較長。 二、喷鼻液(滴)的毒理研究方面: 【實驗材料】 1、喷鼻液(滴劑),每毫升喷鼻液(滴劑)合生藥也物,臨 床以每毫升2g生藥的喷鼻液(滴劑)給藥、小兒每1G公斤體重2滴_ (即約0.1ml)十分鐘内滴完,每十分鐘一次,連續給藥每公斤體重 約0.2g生藥。 2、Wistar大鼠,雌雄兼用體重18〇〜22〇§,由何南醫科大學實 驗動物中心提供。 【方法與結果】 1、急性毒性試驗 取健康大鼠副〜22〇g按體重,性別隨機分為3組,即嘴鼻液(滴籲 劑)高劑量組,低劑量組和空白對照組,每組1〇隻,雌雄各半,實 驗在20 25 C至溫條件下進行,喷鼻液(滴劑)高劑量組滴鼻給予每 毛升3 4g生藥的噴鼻液,低劑量組喷鼻給予每毫升含鉍生藥喷鼻 液’空白對照組滴鼻給予生理鹽水,每次G· lml/kg,1G分鐘内給 凡母10刀知給藥一次,連續給藥1〇次,間隔8小時,然後再重覆 上述給藥過程,累計一日内總給藥量,高劑量組相當於生藥 17 1224005 8g/kg ’低劑量組相當於生藥4g/kg給藥後室溫下飼養,連續觀察 七天,給藥後大鼠的飲水,進食,活動,體重,毛色等均無異常, 詳細情況見下表,七天後將大鼠解剖檢心、肝、脾、肺、腎、胃、 腸、腦、鼻、喉、氣管、支氣管等組織器官,均未見異常改變, 故噴鼻液給大鼠滴鼻給藥8g/kg(相當於生藥的藥)未引起急性毒 性反應,此劑量相當於臨床用量的40倍。 噴鼻液(滴劑)急性毒性試驗結果 器官系統 ------— 給藥後的表現 中樞神經系統及軀體運動 活動自如,對各種刺激的反應無 異常 自主神經系統 瞳孔大小正常 呼吸系統 呼吸平穩,頻率和節律正常,未 見咳嗽哮喘等現象 心血管系統 跳動無異常 胃腸系統 大便成形,無其他異常改變 皮毛 毛色有光澤,皮膚彈性良好,未 ~^^__一_ 見異常 ---—---- 噴鼻液(滴劑)的刺激性試驗 k甩健康大鼠20只,體重18〇〜220g ’隨機分為喷鼻(滴劑)的 組和空白對照,每組10只,雌雄各半,實驗在溫室22±2°C下進行, 、驗^將贺鼻液(滴劑)緩慢滴入大鼠鼻腔,每10分鐘一次,每次 18 1224005 t)斤’連續給藥1岐,貌轉每公㈣能κ含生 nt大既呼吸平穩,呼吸頻率,轉正常,無㈣、哮 而至息專呼吸道不良反應,給藥24小時後解剖大鼠,檢查大谷 -、喉、氣管、支氣管科吸輕膜,均未見充血,铺= 學改變’可靖為喷鼻液(_)伽鼻給藥無她性。、 上述本發明之喷鼻液(_)具有良好的解熱作用,在作強度 ^作用持續_上都·_解鋪安乃近,與進口藥物泰諾退 :口服滴劑侧姻,且無刺激性,按臨床用量_倍(8_生 樂)給大鼠滴鼻未見急性毒性反應,這為其臨床用藥提供了藥理 實驗依據,說明喷鼻液(滴劑)是一個安全性大的醫藥組成物:、 再參閱「表2至表5所示」’係本發明之發燒感冒喷鼻液(滴) 劑療效觀察表。在這些療效觀察表中可看出在不畔齡層使用 下’依不同感f疾病,給予不同的藥劑量,可清楚看出本發明之 發燒感f喷鼻液(滴)劑在患者直接噴(滴)於鼻腔内部,由鼻腔内 部之枯膜吸1後’能在短暫時間上控制住病情,因此在醫療效果 上皆有顯著之醫療效果。 綜上所述本發明以狹葉柴胡、板藍根、大青葉及維生素c之醫 藥組成物,以提取及濾出藥液後,製成可直接噴(滴)於患者之鼻 腔内部,由鼻腔内部之粘膜吸收後,以達治療發燒感冒之疾病, 同時,讓無法吞食藥粒或藥水之患者,提供一極為方便之醫療效 果0 【圖示簡單說明】 19 1224005 圖1,係本發明之發燒感冒喷鼻液(滴)劑之製作流程示意圖。 【表1〜5之簡要說明】 表1,係本發明之發燒感冒喷鼻液(滴)劑對啤酒酵母致熱大鼠體溫 的影響(°C,土SD)示意圖。 表2至表5,係本發明之發燒感冒喷鼻液(滴)劑療效觀察表。
20 1224005 >1
21 1224005 i8/? +1Γ! r 丨S r ¾ §5/6 s、 5/3 —^! 丨6/3
UR Ν «Γ - ϋίλ2 Μ: iyrtTt Μ ±ιτ 4 J:赛: JlllI^ ill 一 2 __3r 4 k纂-# #_η%/12 ±籌 6 51珠鉍e ±無 e ,ί$0 - £、 、5> s zl【z fep |f/2 lig/a 5/2 ft/ 茗 ,0/2 9€ 1!ςπ/2 to 0 骞來;B i^l舲 ,2 3a®>ttWL)»嫌 i?d ί fl· i 一 37 37 1 38*3\ » 4 :gr38 39^-. S β 37一 S6 37*-,e 37 一 | 36' ·£» 道雾 I& 涔^¥1«|鋒7碾^»|失撕|1 薇__潘Hint I雲»恭潯 38· 37 二 »一 0裹# 30· #Ρ·Λ*·»« ^:#_^錄#1| 3a f#·障^__ ^棄氣J;*!丨 39- 39h_T!s!!i!門 391_ϋ ⑷! srsun^Jll^」j-M家濟.虔 WsS;M2’薄»| 审 Ami/12i±lgl4^ 2 * s奉 (3 •卜备丨®!;^:»ί^」!*!*、 ;丨............I丨I丨 :s 4°«#ιι·λ嫌 丨! 4奪簿、声 Is __ δ 39 1 S8 hr ?r 1 丨....^ JODJ sr 3-:«a»J3 §?绘㈣ 3? 37 1-].,,! . 1¾¾ 37 36 -.n S8 36 0S0§S¾着輩·灌 ii^ii …_#和!li„ liii 丨丨 —:_i_i ilili ::...Ητϋ_ :丨 鵁繽#麟||瓣T梁_Η#0ι m 36/ 36 (-』 :^:¾ V: a ;g:^Q5 38, 39 -. 5 3β 3 a” 37 i^JJr 3-aa丨 37」 37 s 38 3? 一 36 36 09 ,:2 :211¾‘ 39上3气 37 1- —8? 热雲1m· 靠露霧論 a^s— $0iswime ~ aM/vw #慨遂产典舞磉Hm-IN^»— 热涔遂米 —^llii叫ί「 M.T£!isMiMliiir^ J!,ni« 丨!热涔,丨 •s讓罐t雜 22 1224005 i 5 |ίγ β s § r 2E1 r
Is 1£:/1 r
Izi
feBT
F 96 s/i 96 fcr
B M 1 0 β #霧零 2^r 磁It I遂 £»?r
#NJ 部着潘 #s JUMM. i葚 ♦鷗 I# * i染激酗 .律条 索 m
I
O m s i c? <N9 h* m tQ.........' Vt* 無 r\s hr 翏!翏 ro Μ ψ〇 iN3 ΙΏ 瓣舉. %
I
I 篇_逢 ϋ S3 s s fg ζλ ica 05 1 C〇 認 zji 丨οσ
L2 QO i aiil.i 1¾ ik»^0 1¾ #11.怜 ¥焉 i^s i.s 1£.,δ ski 讅嬸镳 **# 蜻,·熟 __.黯錄.燐嫌 雲_ 彘»,吩冷讎瓢 β _ _ _ l£ 39 _ 37.
SB 38 iafe 37 37,
K 3气 372 3e, 36 39 一 S8 39 38 37 38 30 39 i 39 38 37 i 38 39 39 36 s ¾ 37 37 38 38 37 g 3? 3β S8 3? 38 38 10* 37 38 37 36 3β 37 36 36 36 37 ¾ 3°. 3K ^ 30? 36 3? 3? 36, 36 S6 ¾ m 37 36 s 36 3eb 1
6R —3— Ρ00^ $$Μ»β0 #_瀘涂遢裊療翥 Ρ00 ♦塞震截 β0 鞒漆連涂 ms^ si β0 #鱭遂米媒舞雋截 si«s;..s.g55s-...l^l.a- I*
I & — *玲s
If +H_£f
If i+H_#^ Λ* f業 #瓤兹涂汫舞寡β_I錄諍#涔 #鶸逢来籲灞案截 ;έ!ί Ρ00$^^β00 «_浼癲第薄 τί # ··1«- / Μ-ψ .................... aM令W tl - - -1.- ...............»»- - -/.fn» 截薄 藩寒 m 0 0, 嘛»典 _3* 23. 1224005 13^~ s/2 d%l_ 營| g/i s Φ j S/2 一 Α4δ 辦 m'fcH#
IgwiliE: 「Μ T irt # δ/2 15#篠磲 β β rw sf/l 坤r 3¾
Fl g/l
F
Is § ggl ^
Jk Μ 3100 41 45 is 50 ω7 42 雕»羚;2Β V rf_T./vrfvv*li <· i / 難wn 43 #«llsr
As l*fill t 1¾ 37 s ?4 45 23 5S 49 41 Μ Jbllt ±輳
I ±薷 h*ls i i
I i i i ¥i ±ll 16 12 16 ie 16 16 16 16 12 12: ο 16 le 14 12 s 14 ±1114
JtJii 14 镎 灣 mwm 58 39
1C 37 aa 39 g
3B S.IMt00^0 IMik舞k鶸 s.s.i -.i#»»· 3.i
SB -ρβ,β$ 3a g 33* 38, 39
3CD f4mt¥0 #_kn^JI^裏 Ρ0.β^β ί
1¾ K ^I 1¾ K ¾ 38 jz! 56 ]¾ ¾ #1¾ 儀舞碓靠羹碓1*1 A嬅雄靠钃澹第Λ
im 蠡溪 llilI 3气 37 37 i 38
30D 38 ¾ 38 se 37 37 ¾ 38 3® 3ΰ 37 36 3β 36 S6 37 37 37 38 g mi* 3:0» 3气
Pm0^ #»ϊ
37 jlnAJMMIL 3ϋ lm 逮洚*舞»# 3?_os6*36_ IMt 遂涞批泠_涔篥》 F,a〜
if SI 37 »!»#Ι1Λ# 一¾ 38 3?- 37 ae s 3β 36 3? 3气
I 10· 3°. 6气 I? 難
I §m 证裹资修 ί$ 蠢 Λ» 截》 1 &0^β *1
I i 24 1224005 >5 fi> lloi/1 E/2 r
IfisJ;ss 慶雄 s
M 卡嫵鸯' s ^migM· 3i Μ i
2Q s 攀 39 30
16 I 3B 全身.不逋 1全身不遽 ζα : 03 03 OB u Γ» m \ta ,3 t& ο» σ» OB 39「姻»*^_^lk 38 37 3?«37· 3B 36 s^*l ^1 _1»1R 1 一1|畢冊It is 18 mwm * #灕.洛舞 m -.ιέ^%» SJl , 用霈㉛確黴 IN**·» C2 _ 洽ί g m a m 0 urns«- 25
Claims (1)
1224005 藍,靛玉紅、谷甾醇、r-谷甾醇以及多種氨基酸。 7·如申請專利範圍第6項所述醫藥組成物,其^,該多種氨基酸為 精氨酸、谷氨酸、路氨酸、脯氨酸、線氨酸、氨基丁酸。 8·如申請專利範圍第1項所述醫藥組成物,其中,該板藍根還含黑 芥子式、靛式、色氨酮,1-硫氰酸—2-羥基丁—3-烯、表告伊春、 腺式、棕櫚酸、蔗糖和含有12%氨基酸的蛋白多糖。 9·如申請專利範園第〗項所述醫藥組成物,其中,該大青葉含靛 藍,搭藍式,款玉紅。 10·如申請專利範圍第1或9項所述醫藥組成物,其中,該大青葉又 含鐵、鈦、猛、鋅、銅以及钻、鎳、硒、路、石_等無機元素。 U·如申請專利範圍第9項所述醫藥組成物,其中,該菘藍 欠解可變為散藍和咬喃木糖嗣酸。 12.山如申請專利範圍第!項所述醫藥組成物,其中,該維生細 碳、氫及氧所組成,分例約為6 ·· 8 ·· 6。 13·-種發燒感时(滴)鼻液劑之製法,其製法之步驟包括: Θ:提T揮發油,將狹葉柴胡先用水浸泡,再加:煎煮,, 水飢讀法提取揮發油,再遽出藥液,再 出液和藥殘渣分別用容器暫存; 、x/ b)、將板錄、大料相力认水煎錢 液用容器暫存; 龙過遽’將過3 C)、係將 步驟及b步驟提取及過舰_於之藥殘渣混 27 1224005 合後,再加入藥殘渣混合後之倍數量之水煎煮,再濾出液; 再加入藥殘渣倍數量之水再煎煮,再濾出液合併; d) 、合併上述a、b、^三份濾出液,並濃縮藥液,再將前述 放冷加入乙醇; e) 、再將上述之藥液靜置數小時,過濾,回收乙醇; f) 、再將上述之揮發油及維生素C,溶解後加入上述之藥液 中,混合過濾後,分裝即得。 14·如申請專利範團第13項所述之發燒感冒喷(滴)鼻液劑之製 去其中,该狹葉柴胡提取揮發油時,先以一倍水浸泡2小時, 並再加入四倍水煎煮。 15·如申請專利範圍第13項所述之發燒感冒喷(滴)鼻液劑之製 法’其中,該狹葉柴胡所提取之揮發油約在2na〜2.4ml。 16·如申請專利範圍第13項所述之發燒感冒喷(滴)鼻液劑之製 法其中,该狹葉柴胡在提取揮發油後,再濾出藥液約 1000ml〜1200ml 。 17·如申請專利範圍第13項所述之發燒感冒喷(滴)鼻液劑之製 法其中’該板藍根、大青葉加入七倍水煎煮1小時。 18·如申請專利範圍第13項所述之發燒感冒喷(滴)鼻液劑之製 法,其中,該a步驟及b步驟提取及過濾後所剩於之藥殘渣混合 後,再加入藥殘渣混合後之五倍量水煎煮丨小時。 19·如申料利範圍第酬所述之發燒感时(滴)鼻液劑之製 28 法,其中,該a步驟及b步驟提取及過濾後所剩於之藥殘渣混合 煎煮,並濾出液後,再加入四倍量水煎煮1小時。 20·如申請專利範圍第13項所述之發燒感冒喷(滴)鼻液劑之製 法’其中,該a、b、c步驟之三份濾出液濃縮藥液約在imi相當 於lg生藥。 21·如申請專利範圍第13項所述之發燒感冒喷(滴)鼻液劑之製 法’其中,該a、b、c步驟之三份濾出液濃縮後置冷再加入95% 乙醇到合醇量70%。 22·如申請專利範圍第13項所述之發燒感冒喷(滴)鼻液劑之製 法,其中,該乙醇回收到約lml含生藥lg。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW87114505A TWI224005B (en) | 1998-09-02 | 1998-09-02 | Pharmaceutical composition for nasal spray in treatment of cold and fever and method for producing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW87114505A TWI224005B (en) | 1998-09-02 | 1998-09-02 | Pharmaceutical composition for nasal spray in treatment of cold and fever and method for producing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TWI224005B true TWI224005B (en) | 2004-11-21 |
Family
ID=34568099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW87114505A TWI224005B (en) | 1998-09-02 | 1998-09-02 | Pharmaceutical composition for nasal spray in treatment of cold and fever and method for producing the same |
Country Status (1)
| Country | Link |
|---|---|
| TW (1) | TWI224005B (zh) |
-
1998
- 1998-09-02 TW TW87114505A patent/TWI224005B/zh not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102488833B (zh) | 一种具有疏风宣肺退热止咳功效的中药制剂 | |
| CN103110730A (zh) | 一种治疗哮喘的苏子芩杏汤剂及其制备方法 | |
| CN101411782A (zh) | 一种治疗急性咽炎的药物组合物及其制备方法 | |
| CN103977314A (zh) | 一种治疗呼吸道疾病的药物组合物及制备方法和用途 | |
| CN105748900A (zh) | 一种治疗慢性咽喉炎的中药及其制备方法 | |
| CN103494962B (zh) | 一种清热解毒的中药组合物 | |
| CN104324125B (zh) | 一种治疗慢性咽炎的中药组合物及其制备方法 | |
| CN110237174A (zh) | 一种治疗感冒咳嗽的燥湿中药组合物及其制备方法 | |
| CN103041030B (zh) | 一种治疗大头瘟的药物组合物及其制备方法和用途 | |
| CN102139051B (zh) | 清热解毒软胶囊在制备用于治疗病毒性肺炎药物中的应用 | |
| CN102512552A (zh) | 一种治疗外感发热的中药组合物 | |
| CN114748603B (zh) | 一种防治新冠病毒肺炎变异或复阳的药物组合物和应用 | |
| TWI224005B (en) | Pharmaceutical composition for nasal spray in treatment of cold and fever and method for producing the same | |
| CN104225200A (zh) | 一种治疗饮凌心肺型心源性哮喘的中药及制备方法 | |
| CN104435560B (zh) | 缓解麻醉消失后切口疼痛的中药组合物及制备方法 | |
| CN103272111A (zh) | 治疗牙痛的中药药液 | |
| WO2006094460A1 (en) | A medicine for treating cough and asthma and preparation method thereof | |
| CN102861258B (zh) | 一种治疗神昏的药物组合物及其制备方法和用途 | |
| CN102106999A (zh) | 一种治疗中风病后吞咽困难的中药复方制剂及其制备方法 | |
| CN102198182A (zh) | 一种治疗间质性肺炎的药物 | |
| CN109106842B (zh) | 一种用于戒烟的药物及其制备方法 | |
| CN107095977A (zh) | 一种具有祛火排毒功效的药剂及其药物配方和制备方法 | |
| CN101199753B (zh) | 一种治疗燥热咳嗽型咯血的内服中药 | |
| CN119326825A (zh) | 一种经典名方麻黄汤的制备方法 | |
| CN107029058A (zh) | 一种治疗慢性咽炎的中药组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4A | Expiration of patent term of an invention patent |